Novartis Wins U.S. Approval for First of New Psoriasis Drugs
This article is for subscribers only.
Novartis AG won U.S. approval for the first in a new line of psoriasis drugs that aim to better treat the itchy, sometimes debilitating skin condition.
The Food and Drug Administration cleared the treatment to be called Cosentyx. The medicine, also known as secukinumab, is predicted to top $1 billion in sales by 2020 and will compete with other biologic drugs including AbbVie Inc.’s No. 1 seller, Humira, and Amgen Inc.’s best-selling Enbrel. The therapy was backed in November by European Commission health regulators.